Literature DB >> 15963163

Brief report: attitudes toward hormone therapy after the Women's Health Initiative: a comparison of internists and gynecologists.

Allan S Brett1, Patricia I Carney, Robert E McKeown.   

Abstract

In the Women's Health Initiative (WHI), postmenopausal women receiving combination hormone therapy (HT) experienced more adverse outcomes than placebo recipients. To determine whether gynecologists and internists interpreted the WHI differently, we conducted a survey in which physicians responded to a hypothetical asymptomatic woman who asks whether to continue HT. In response to this scenario, gynecologists were more likely than internists to hold permissive views about prescribing HT (66% vs 35%; P<.001). These results suggest that gynecologists may be less concerned than internists about the adverse events associated with HT, or that gynecologists have stronger beliefs about benefits of HT.

Entities:  

Mesh:

Year:  2005        PMID: 15963163      PMCID: PMC1490120          DOI: 10.1111/j.1525-1497.2005.0089.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  17 in total

1.  Effects of different monetary incentives on the return rate of a national mail survey of physicians.

Authors:  J B VanGeest; M K Wynia; D S Cummins; I B Wilson
Journal:  Med Care       Date:  2001-02       Impact factor: 2.983

2.  Comparison of e-mail, fax, and postal surveys of pediatricians.

Authors:  Shawn R McMahon; Martha Iwamoto; Mehran S Massoudi; Hussain R Yusuf; John M Stevenson; Felicita David; Susan Y Chu; Larry K Pickering
Journal:  Pediatrics       Date:  2003-04       Impact factor: 7.124

3.  Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale.

Authors: 
Journal:  Ann Intern Med       Date:  2002-11-19       Impact factor: 25.391

4.  Studies with low response proportions may be less biased than studies with high response proportions.

Authors:  Andreas Stang; Karl-Heinz Jöckel
Journal:  Am J Epidemiol       Date:  2004-01-15       Impact factor: 4.897

Review 5.  Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy.

Authors: 
Journal:  Menopause       Date:  2003 Jan-Feb       Impact factor: 2.953

6.  Provider attitudes and self-reported behaviors related to hormone replacement therapy.

Authors:  S J Rolnick; R A Kopher; R B Compo; M E Kelley; T A DeFor
Journal:  Menopause       Date:  1999       Impact factor: 2.953

7.  Effects of estrogen plus progestin on health-related quality of life.

Authors:  Jennifer Hays; Judith K Ockene; Robert L Brunner; Jane M Kotchen; JoAnn E Manson; Ruth E Patterson; Aaron K Aragaki; Sally A Shumaker; Robert G Brzyski; Andrea Z LaCroix; Iris A Granek; Barbara G Valanis
Journal:  N Engl J Med       Date:  2003-03-17       Impact factor: 91.245

8.  Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Authors:  Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

9.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

10.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

Authors:  Adam L Hersh; Marcia L Stefanick; Randall S Stafford
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

View more
  6 in total

1.  Self-reported changes in providers' hormone therapy prescribing and counseling practices after the Women's Health Initiative.

Authors:  Susan L Lakey; Susan D Reed; Andrea Z LaCroix; Lou Grothaus; Katherine M Newton
Journal:  J Womens Health (Larchmt)       Date:  2010-11-09       Impact factor: 2.681

2.  Combined hormone therapy at menopause and breast cancer: a warning--short-term use increases risk.

Authors:  Leslie Bernstein
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

3.  How the Women's Health Initiative (WHI) influenced physicians' practice and attitudes.

Authors:  Terry M Bush; Amy E Bonomi; Larissa Nekhlyudov; Evette J Ludman; Susan D Reed; Maureen T Connelly; Lou C Grothaus; Andrea Z LaCroix; Katherine M Newton
Journal:  J Gen Intern Med       Date:  2007-07-18       Impact factor: 5.128

4.  Determinants of hormone therapy discontinuation among female veterans nationally.

Authors:  Sally G Haskell; Bevanne Bean-Mayberry; Joseph L Goulet; Melissa Skanderson; Chester B Good; Amy C Justice
Journal:  Mil Med       Date:  2008-01       Impact factor: 1.437

5.  Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: an analysis of published articles.

Authors:  Adriane Fugh-Berman; Christina Pike McDonald; Alicia M Bell; Emily Catherine Bethards; Anthony R Scialli
Journal:  PLoS Med       Date:  2011-03-15       Impact factor: 11.069

6.  Sources of information influencing the state-of-the-science gap in hormone replacement therapy usage.

Authors:  Fiona Chew; Xianwei Wu
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.